Drug intelligence / Profile preview

zovaglutide + rosuvastatin + digoxin

Development stage
Unknown
Lead developer
QL Biopharm
Modality
Peptides, Small Molecules
Administration
Subcutaneous, Oral
01

Overview

ZT002 + rosuvastatin + digoxin is a drug combination evaluated in a Phase 1 drug-drug interaction (DDI) study. ZT002 (zovaglutide) is an ultra long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) developed by Beijing QL Biopharmaceutical for the treatment of obesity and type 2 diabetes. Rosuvastatin is an HMG-CoA reductase inhibitor (statin) used for lipid management, and digoxin is a cardiac glycoside used for heart failure and arrhythmias. The combination is specifically studied to determine if the administration of ZT002 affects the pharmacokinetics of rosuvastatin and digoxin, which are common co-medications in the target patient population.

Other names
zovaglutide + rosuvastatin + digoxin
02

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)GLP1R (GLP-1R)

Beyond the preview

Go deeper on zovaglutide + rosuvastatin + digoxin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on zovaglutide + rosuvastatin + digoxin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call